Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606.

Article  PubMed  PubMed Central  Google Scholar 

Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma [updated 2023 June 12] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan-. 2023. https://www.ncbi.nlm.nih.gov/pubmed/32644603. Accessed 5 Dec 2023.

Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223–40.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Hepatocellular carcinoma version 2. 2023. https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf. Accessed 5 Dec 2023.

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.

Article  PubMed  Google Scholar 

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.

Article  PubMed  Google Scholar 

Su GL, Altayar O, O’Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920–34.

Article  PubMed  Google Scholar 

Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960–74.

Article  CAS  PubMed  Google Scholar 

Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–65.

Article  PubMed  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):1–12.

Article  Google Scholar 

Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506–15.

Article  CAS  PubMed  Google Scholar 

Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90.

Article  CAS  PubMed  Google Scholar 

Keam SJ. Tremelimumab: first approval. Drugs. 2023;83(1):93–102.

Article  CAS  PubMed  Google Scholar 

AstraZeneca Pharmaceuticals LP. Imjudo - tremelimumab injection, solution: US prescribing information. 2023. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289. Accessed 5 Dec 2023.

AstraZeneca. Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers. 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers.html. Accessed 5 Dec 2023.

AstraZeneca AB. Imjudo: summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo#product-information-section. Accessed 5 Dec 2023.

Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. [abstract no. 3802]. Cancer Res. 2004;64(7_Suppl):877.

Google Scholar 

Center for Drug Evaluation and Research (CDER). Tremelimumab (Imjudo) multi-discipline review. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761289Orig1s000MultidisciplineR.pdf. Accessed 5 Dec 2023.

Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol. 2021;39(27):2991–3001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song X, Kelley RK, Khan AA, et al. Exposure-response analyses of tremelimumab monotherapy or in combination with durvalumab in patients with unresectable hepatocellular carcinoma. Clin Cancer Res. 2023;29(4):754–63.

Article  CAS  PubMed  Google Scholar 

Lim K, Abegesah A, Fan C, et al. Population pharmacokinetics and exposure-response analysis of tremelimumab 300 mg single dose combined with durvalumab 1500 mg Q4W (STRIDE) in patients with unresectable hepatocellular carcinoma. J Clin Pharmacol. 2023;63(11):1221–31.

Article  CAS  PubMed  Google Scholar 

Sangro B, Chan S, Kelley R, et al. Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma [abstract no. SO-15 plus presentation]. Ann Oncol. 2023;34(Suppl 1):S168.

Article  Google Scholar 

Qin L, Miranda M, Shephard C, et al. The impact of treatment and treatment status on health state utility in patients with unresectable hepatocellular carcinoma: an EQ-5D analysis from Himalaya [abstract no. OS161]. J Hepatol. 2022;77(Suppl 1):S110.

Article  Google Scholar 

Lau G, Sangro B, Crysler OV, et al. Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) [abstract no. 4073]. J Clin Oncol. 2023;41(16_Suppl).

Lau G, Cheng A-L, Sangro B, et al. Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) [abstract no. 4004]. J Clin Oncol. 2023;41(16_Suppl).

Article  Google Scholar 

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

Article  CAS  PubMed  Google Scholar 

Greten TF, Abou-Alfa G, Cheng A, et al. Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2023. doi.org/10.1136/jitc-2021-002794add1.

European Medicines Agency (EMA). EMA recommends extenstion of indications for durvalumab in the management of HCC. 2023. https://www.esmo.org/oncology-news/. Accessed 5 Dec 2023.

Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2023;53(5):383–90.

Article  PubMed  Google Scholar 

European Medicines Agency (EMA). ESMO-MCBS Scorecards. Tremelimumb. Himalaya. 2023. https://www.esmo.org/guidelines/. Accessed 5 Dec 2023.

Fulgenzi CAM, D’Alessio A, Airoldi C, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. Eur J Cancer. 2022;174:57–67.

Article  CAS  PubMed  Google Scholar 

Qin L, Chan S, Le Nouveau P, et al. Matching adjusted indirect comparison (MAIC) of single tremelimumab regular interval durvalumab (STRIDE) versus atezolizumab with bevacizumab (A+B) for the treatment of unresectable hepatocellular carcinoma (UHCC) [abstract no. CO70]. Value Health. 2023;26(6 Suppl. 2):S27.

Hatanaka T, Naganuma A, Yata Y, et al. Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? Hepatobiliary Surg Nutr. 2022;11(6):927–30.

Article  PubMed  PubMed Central  Google Scholar